PitchSend

Investor Presentaiton

37 B-cell function Investor presentation Full year 2022 Diabetes is a chronic disease requiring treatment intensification over time Diet and exercise OAD GLP-1 Distribution of patients and value across treatment classes 44% 3% 13% 20% 2% 9% 31% Insulin 10% 9% 27% 30% Time Patients Insulin SGLT-2i GLP-1 Inj. Value Oral GLP-1 DPP-4i Trad. OAD Note: Patient distribution across treatment classes is indicative and based on data for USA, Germany, France. Other OADS cover: metformin, sulfonylurea, thiazolidinediones. Source: IQVIA PharMetrix claims data, IQVIA disease analyser, IQVIA MIDAS; value figures based on IQVIA MAT, Nov 2022 OAD: Oral anti-diabetic Novo NordiskⓇ

View entire presentation